Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.57 |
| ▸ | PI4KA | P42356 | 18/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 18/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 16/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.57 |
| ▸ | PIP5K1C | O60331 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852070 | 0.82 | ALKBH5 (0.61) | PIK3CAPI4KAPI4KBPIK3CDPIK3CB | |
| SCHEMBL13412878 | 0.82 | PI4KA (0.80) | PIK3CAPI4KAPI4KBPIK3CDPIK3CB | |
| SCHEMBL13412968 | 0.81 | CYP3A4 (0.63) | PIK3CAPI4KAPI4KBPIK3CDPIK3CB | |
| SCHEMBL1853965 | 0.80 | CYP3A4 (0.62) | PIK3CAPI4KAPI4KBPIK3CDPIK3CB | |
| SCHEMBL9399572 | 0.79 | S1PR1 (0.49) | CYP3A4 | |
| SCHEMBL5946843 | 0.78 | CYP3A4 (0.78) | PIK3CAPI4KAPI4KBPIK3CDPIK3CB | |
| SCHEMBL9399442 | 0.77 | S1PR1 (0.51) | CYP3A4 | |
| SCHEMBL6811786 | 0.75 | CYP3A4 (0.72) | PIK3CAPI4KAPI4KBPIK3CDPIK3CB | |
| SCHEMBL11344342 | 0.75 | CYP3A4 (0.72) | PIK3CAPI4KAPI4KBPIK3CDPIK3CB | |
| SCHEMBL16240828 | 0.75 | CYP3A4 (0.72) | PIK3CAPI4KAPI4KBPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | APP, APBA1, PYGB | PIK3CA 4138/4885PI4KA 4376/4885PI4KB 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.